MODELING THE IMPACT OF THE VACCINE CANDIDATE TAK-003 ON THE INCIDENCE OF DENGUE IN FRENCH OVERSEAS TERRITORIES

被引：0
|
作者：
Nucit, A. [1 ]
Moreau, R. [2 ]
Massetti, M. [2 ]
Strub, C. [3 ]
Kharitonova, E. [4 ]
Tytula, A. [5 ]
Zawieja, J. [5 ]
Leleu, H. [2 ]
Shen, J. [6 ]
机构：
[1] Takeda France SAS, F-75 Paris, France
[2] Publ Hlth Expertise, F-75 Paris, France
[3] Takeda France SAS, Paris, France
[4] Putnam PHMR, Paris, France
[5] Putnam PHMR, Krakow, Poland
[6] Takeda Pharmaceut Int AG, Zurich, Switzerland
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EPH47
引用
收藏
页码：S211 / S211
页数：1
相关论文
共 46 条
  • [31] Travel medicine providers' opinions on the dengue vaccine TAK-003 as a travel vaccine and the need for decision-support information and materials before its launch in Japan
    Fukunishi, Atsuko
    Machida, Masaki
    Fukushima, Shinji
    Inoue, Shigeru
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2025, 21 (01)
  • [32] Safety signal detected: Anaphylaxis after attenuated dengue vaccine (TAK-003) - Brazil, march 1, 2023-march 11, 2024
    Percio, Jadher
    Kobayashi, Carla Dinamerica
    Silva, Roberta Mendes Abreu
    Marinho, Ana Karolina Barreto Berselli
    Capovilla, Leon
    Andrade, Paulo Henrique Santos
    da Nobrega, Martha Elizabeth Brasil
    Cabral, Cibelle Mendes
    de Moraes, Monica Brauner
    Werneck, Guilherme Loureiro
    Fernandes, Eder Gatti
    VACCINE, 2024, 42 (26)
  • [33] IgG, IgM, and Nonstructural Protein 1 Response Profiles after Receipt of Tetravalent Dengue Vaccine TAK-003 in a Phase 2 Randomized Controlled Trial
    Low, Jenny G.
    Oh, Helen M.
    Leo, Yee-Sin
    Kalimuddin, Shirin
    Wijaya, Limin
    Pang, Junxiong
    Lee, Tau Hong
    Moss, Kelley J.
    Brose, Manja
    Tricou, Vianney
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2024, 111 (01): : 102 - 106
  • [34] A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country
    Tricou, Vianney
    Eyre, Susannah
    Ramjee, Mahadev
    Mojares, Zenaida
    Collini, Paul
    Loeliger, Edde
    Mandaric, Sanja
    Rauschera, Martina
    Brose, Manja
    Lefevre, Inge
    Folschweiller, Nicolas
    Wallace, Derek
    VACCINE, 2023, 41 (07) : 1398 - 1407
  • [35] ASSESSING THE VALUE OF DENGUE VACCINE TAK 003: A COST-EFFECTIVENESS STUDY IN MALAYSIA
    Azzeri, A.
    Jaafar, H.
    Ting, R.
    Langer, J.
    Dahlui, M.
    VALUE IN HEALTH, 2024, 27 (12) : S110 - S111
  • [36] Impact of TAK-003 on epidemiologic, economic and quality-of-life burden of dengue: comparison of the results from a dynamic transmission model and a static model with a dynamic component
    Kharitonova, Elizaveta
    Shen, Jing
    Tytula, Anna
    Zawieja, Justyna
    Rojas, Yaneth Gil
    Aballea, Samuel
    Hanley, Riona
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2025, 152
  • [37] Assessing the Potential of a Candidate Dengue Vaccine with Mathematical Modeling
    Beatty, Mark
    Boni, Maciej F.
    Brown, Shawn
    Buathong, Rome
    Burke, Donald
    Coudeville, Laurent
    Cummings, Derek A. T.
    Edelman, Robert
    Farrar, Jeremy
    Focks, Dana A.
    Gomes, M. Gabriela M.
    Guignard, Adrienne
    Halstead, Scott
    Hombach, Joachim
    Knerer, Gerhart
    Koelle, Katia
    Lam, Fook Chang
    Lang, Jean
    Longini, Ira
    Medlock, Jan
    Namgyal, Pem
    Powell, Mair
    Recker, Mario
    Rohani, Pejman
    Standaert, Baudoin
    Struchiner, Claudio
    Teyssou, Remy
    Wearing, Helen
    PLOS NEGLECTED TROPICAL DISEASES, 2012, 6 (03):
  • [38] Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4.5-year results from a phase 3, randomised, double-blind, placebo-controlled trial
    Tricou, Vianney
    Yu, Delia
    Reynales, Humberto
    Biswal, Shibadas
    Saez-Llorens, Xavier
    Sirivichayakul, Chukiat
    Lopez, Pio
    Borja-Tabora, Charissa
    Bravo, Lulu
    Kosalaraksa, Pope
    Vargas, Luis Martinez
    Alera, Maria Theresa
    Rivera, Luis
    Watanaveeradej, Veerachai
    Dietze, Reynaldo
    Fernando, Lakkumar
    Wickramasinghe, V. Pujitha
    Moreira Jr, Edson Duarte
    Fernando, Asvini D.
    Gunasekera, Dulanie
    Luz, Kleber
    Oliveira, Ana Lucia
    Tuboi, Suely
    Escudero, Ian
    Hutagalung, Yanee
    Lloyd, Eric
    Rauscher, Martina
    Zent, Olaf
    Folschweiller, Nicolas
    LeFevre, Inge
    Espinoza, Felix
    Wallace, Derek
    LANCET GLOBAL HEALTH, 2024, 12 (02): : E257 - E270
  • [39] Exanthema after dengue vaccine (TAK003): first data of passive surveillance in a private vaccination center in Argentina
    Castellano, Vanesa E.
    Orduna, Tomas
    Burgos, Fernando
    Leiro, Viviana
    Sosa, Nadia
    Bonvehi, Pablo
    MEDICINA-BUENOS AIRES, 2024, 84 (05) : 852 - 859
  • [40] An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life
    Patel, Sanjay S.
    Winkle, Peter
    Faccin, Alice
    Nordio, Francesco
    LeFevre, Inge
    Tsoukas, Claudia Galindo
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (02)
12345